Myasthenia Gravis: Symptoms, Diagnosis, and Treatment

What is Myasthenia Gravis?

Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by fluctuating muscle weakness and severe, exercise-induced fatigue. It affects the skeletal muscles, which are responsible not only for the movement of the limbs but also for vital functions like breathing, swallowing, and facial expression.

What Does the Name Mean?

The name derives from both Greek and Latin:

• Greek: myasthéneia (μυασθένεια), meaning “muscle weakness”, comes from mys (muscle) and asthéneia (weakness).
• Latin: gravis, meaning “severe” or “weighty”.

Together, “severe muscle weakness” perfectly captures the condition’s defining feature.

How It Presents

The hallmark symptom of myasthenia gravis is muscular weakness that worsens with physical activity and improves with rest. This fluctuating pattern is characteristic and helps distinguish it from many other causes of muscle weakness. While any skeletal muscle can be affected, those most commonly involved include the muscles controlling:

• Eye movement and eyelid position
• Facial expression
• Chewing (mastication)
• Speech
• Swallowing (deglutition)
• Arm and leg movement
• Breathing (in severe cases)
• Neck posture

Prognosis and Quality of Life

While there is no definitive cure for myasthenia gravis, modern treatments enable effective symptom control in the vast majority of patients. With appropriate management, most individuals with myasthenia gravis can achieve a satisfactory quality of life. Life expectancy, with rare exceptions, is essentially normal in well-managed patients.

---

Cause

Myasthenia gravis occurs due to a defect in the transmission of nerve impulses to muscles at the neuromuscular junction (NMJ). This is the specialized synaptic connection between motor nerve terminals and skeletal muscle fibers.

Normal Neuromuscular Transmission

Under normal circumstances:

1. A nerve impulse travels down the motor neuron.
2. The nerve terminal releases acetylcholine (ACh), a neurotransmitter, into the NMJ.
3. ACh binds to acetylcholine receptors (AChR) on the muscle fiber surface.
4. This binding generates an electrical signal in the muscle, triggering contraction.

What Goes Wrong in Myasthenia Gravis

In myasthenia gravis, the immune system produces pathological autoantibodies that target and attack components of the NMJ. The most clinically important are:

• Anti-AChR antibodies: Present in approximately 85% of patients with generalized myasthenia gravis. These antibodies bind to AChRs, causing their destruction, internalization, and complement-mediated damage. This process dramatically reduces the number of functional receptors available for acetylcholine binding.
• Anti-MuSK antibodies (Muscle-Specific Kinase): Present in a significant proportion of AChR antibody-negative patients. MuSK is a protein essential for clustering AChRs at the NMJ; its disruption impairs NMJ organization.
• Anti-LRP4 antibodies: A less common but increasingly recognized autoantibody target.

The result is that ACh, even when released normally, cannot effectively bind to sufficient receptors. Because of this, the final step of neuromuscular signal transmission fails, and muscle contraction is impaired.

This is a autoimmune disease: the body’s immune system mistakenly attacks its own healthy tissues.

The Role of the Thymus

The thymus gland, located in the central chest just below the neck, plays a critical role in immune system development. It is especially important for producing T lymphocytes, which learn to distinguish “self” from “non-self” tissues. Under normal circumstances, the thymus atrophies after puberty and is largely replaced by fatty tissue.

In many adults with myasthenia gravis:

• The thymus fails to atrophy appropriately and remains abnormally active.
• Up to 75% of myasthenia gravis patients have thymic abnormalities, such as thymic hyperplasia (enlargement) or a thymoma. A thymoma is a benign thymic tumor and is present in approximately 10–15% of cases.

While the precise mechanism linking thymic pathology to autoantibody production is not fully established, the thymus is believed to send aberrant immune instructions that lead developing immune cells to attack AChRs. This relationship is clinically important because removal of the thymus (thymectomy) is an established treatment that can significantly improve or even resolve myasthenia gravis symptoms.

Risk Factors

• Myasthenia gravis affects both men and women and occurs across all ethnicities.
• It is more common in young women under 40 and older men over 60, but can begin at any age, including childhood.
• It is not hereditary (not directly passed from parent to child) and is not contagious.
• Occasionally, it may affect more than one member of the same family.

Neonatal and Congenital Myasthenia

• Neonatal myasthenia gravis: Babies born to mothers with myasthenia gravis may temporarily acquire maternal autoantibodies across the placenta, causing transient muscular weakness. This is self-limiting and typically resolves within 2 to 3 months as maternal antibodies are cleared.
• Congenital myasthenic syndromes: Rare conditions caused by genetic mutations affecting NMJ proteins (not autoimmune in origin). These are distinct from autoimmune myasthenia gravis.

---

Symptoms

While myasthenia gravis can affect any skeletal muscle, the most commonly and often most prominently involved are those controlling:

• Eyes and eyelid movement
• Facial expression
• Swallowing

Onset

The onset of symptoms can be sudden or insidious. It is unfortunately common for symptoms to go unrecognized or misattributed to other conditions for months or even years before the correct diagnosis is established.

Most Common Presenting Symptoms

Ocular Symptoms (Most Frequent First Manifestation)

In the majority of patients, the first evident symptom is weakness of the eye muscles:

• Ptosis: Drooping of one or both eyelids, often worse as the day progresses or after sustained use.
• Diplopia: Double vision or blurred vision caused by weakness of the extraocular muscles controlling eye movement.

In some patients, myasthenia remains confined to the ocular muscles (ocular myasthenia) and never progresses further. In approximately 50–80% of patients with initial ocular symptoms, the disease generalizes within two years.

Bulbar Symptoms

• Dysphagia: Difficulty swallowing, which may cause choking or aspiration.
• Dysarthria: Slurred or nasal speech, worsening with prolonged talking.
• Facial weakness: Changed facial expression (difficulty smiling, pursing lips, or puffing cheeks).
• Jaw fatigue: Difficulty chewing, particularly tough foods; the jaw may drop.

Limb and Respiratory Weakness

• Dyspnea (breathlessness): This becomes especially serious when the muscles of respiration are involved, as this represents the most dangerous complication.
• Weakness of arms, hands, fingers, legs, and neck: Leading to difficulty with activities requiring sustained muscle use (lifting objects, climbing stairs, combing hair, rising from a chair).

Key Characteristics of Myasthenia Gravis Weakness

Myasthenic Crisis

A myasthenic crisis is a medical emergency defined by the failure of respiratory muscles to maintain adequate ventilation. It requires immediate medical intervention, usually in the form of mechanical respiratory support.

• Approximately 1 in 5 patients (20%) will experience at least one myasthenic crisis during their lifetime.
• It requires urgent hospital admission and may require intensive care unit management.

Common triggers include:

• Infections (particularly respiratory infections, the most frequent trigger)
• Emotional or physical stress
• Surgical procedures and anesthesia
• Adverse drug reactions: Many medications can precipitate or worsen myasthenic crisis, including aminoglycoside antibiotics, beta-blockers, fluoroquinolones, magnesium, and some neuromuscular blocking agents.

In many cases, no specific trigger can be identified.

Warning signs of impending myasthenic crisis: Rapid worsening of breathing difficulty, increasing inability to swallow secretions, or rapidly progressive generalized weakness (especially if it occurs after an intercurrent illness) should prompt immediate emergency evaluation. Instead, watch for these signs, particularly when they follow a recent illness, as they require urgent medical attention. Instead, watch for these symptoms, especially after a recent illness, as they require urgent medical attention.

---

Diagnosis

Myasthenia gravis is notoriously challenging to diagnose, because muscular weakness is a symptom shared by many conditions and the fluctuating nature of myasthenia can make clinical assessment at any single point misleading. The diagnostic process typically involves a combination of clinical evaluation, bedside tests, and laboratory/instrumental investigations.

Unfortunately, the diagnostic journey often takes years before a definitive conclusion is reached. This delay reinforces the importance of specialist neurological evaluation in patients with unexplained, fluctuating muscle weakness.

Ice Pack Test

The ice pack test is used for patients with prominent eyelid drooping (ptosis).

Procedure: An ice pack is placed gently over the closed eye(s) for two minutes.

Interpretation: A temporary improvement in ptosis following the application of cold (which temporarily enhances NMJ function by slowing acetylcholinesterase activity) strongly suggests myasthenia gravis as the underlying cause.

Rest Test

The rest test is used to evaluate weakness of the extraocular muscles, typically manifesting as double vision.

Procedure:

1. The patient is asked to use their eye muscles until clearly fatigued.
2. The patient then lies down in a darkened room with eyes closed for several minutes.

Interpretation: If extraocular muscle function improves noticeably after rest, and double vision diminishes, myasthenia gravis is considered a likely diagnosis.

Laboratory and Instrumental Tests

Serological Tests (Blood Tests)

• Anti-AChR antibodies: Elevated in approximately 85% of generalized myasthenia gravis patients and ~50% of ocular myasthenia patients. A positive result is highly specific for myasthenia gravis.
• Anti-MuSK antibodies: Present in the majority of AChR antibody-negative patients with generalized myasthenia.
• Anti-LRP4 antibodies: Detectable in some seronegative patients.

Important: A negative antibody test does not exclude myasthenia gravis. Seronegative myasthenia gravis (with no detectable standard antibodies) is a recognized entity, and diagnosis rests on the clinical picture and other confirmatory tests.

Edrophonium (Tensilon) Test

Edrophonium chloride is a short-acting acetylcholinesterase inhibitor that transiently increases acetylcholine availability at the NMJ. Intravenous injection produces a brief but often dramatic improvement in muscle strength in patients with myasthenia gravis (typically within 1–2 minutes, lasting 5–10 minutes).

Due to potential cardiac side effects, this test requires careful monitoring and is now less commonly performed than in the past, with serological and electrophysiological testing often preferred.

Electrophysiological Studies

• Electromyography (EMG): Specifically, repetitive nerve stimulation (RNS) at low frequencies reveals a characteristic decremental response. This response involves a progressive reduction in muscle action potential amplitude with repeated stimulation. The finding reflects NMJ transmission failure during repeated activation in myasthenia gravis.
• Single-fiber EMG (SFEMG): The most sensitive test for NMJ dysfunction, demonstrating increased jitter (variability in the timing of individual muscle fiber firing) in affected muscles. SFEMG is positive in over 95% of myasthenia gravis cases.

Imaging Studies

• CT scan or MRI of the chest: These are essential for evaluating the thymus. They help detect thymoma or thymic hyperplasia, conditions that significantly influence treatment decisions.

---

Can It Be Cured?

At present, there is no definitive cure for myasthenia gravis. However, modern treatments have transformed the prognosis of this disease dramatically:

• The vast majority of patients achieve excellent symptom control with available therapies.
• Life expectancy is essentially normal for most well-managed patients. This stands in marked contrast to the historical mortality from myasthenic crises and respiratory failure.
• The disease typically worsens slowly over time, though symptom severity fluctuates.

Some patients experience remission, which may be temporary or permanent. During remission, muscle weakness disappears completely, and medication can be tapered or discontinued. However, relapse remains possible even after prolonged periods of remission.

Myasthenic crises can occur at any point in the disease course and require immediate medical management.

---

Treatment

Despite the absence of a definitive cure, myasthenia gravis is generally well-manageable with the following approaches:

Thymectomy (Thymus Removal)

Surgical removal of the thymus (thymectomy) is strongly recommended for patients with thymoma and is also indicated for many patients without thymoma, particularly those with generalized myasthenia gravis under the age of 60.

• Thymectomy frequently leads to significant reduction or complete remission of symptoms.
• In approximately 50% of patients, thymectomy ultimately enables discontinuation of all other medications.
• A landmark randomized clinical trial (MGTX trial) confirmed that thymectomy significantly improves clinical outcomes compared to medical therapy alone in AChR antibody-positive generalized myasthenia.

Acetylcholinesterase Inhibitors

Drugs such as pyridostigmine (Mestinon®) inhibit the enzyme that breaks down acetylcholine, thereby increasing its availability at the NMJ and enhancing neuromuscular transmission.

• These are typically the first-line symptomatic treatment for myasthenia gravis.
• They do not modify the underlying autoimmune disease but provide reliable symptomatic relief for most patients.
• Side effects include gastrointestinal cramping, increased secretions, and fasciculations. These are generally manageable with dose adjustment.

Immunosuppressive Therapy

For patients with insufficient response to acetylcholinesterase inhibitors, or to achieve disease modification, immunosuppressive drugs are introduced to suppress the production of pathological autoantibodies:

All immunosuppressive agents carry potential significant side effects (infection susceptibility, metabolic effects, bone density loss, hepatotoxicity, etc.) and require close, ongoing medical monitoring.

Plasmapheresis (Plasma Exchange) and Intravenous Immunoglobulins (IVIg)

These are rapid-acting but short-lived treatments reserved for:

• Myasthenic crises (emergency treatment)
• Pre-operative preparation for thymectomy or other surgery
• Refractory cases failing other treatments

Plasmapheresis filters the patient’s blood to physically remove circulating autoantibodies. IVIg provides a pool of normal antibodies that modulate the immune response.

Both approaches produce effects lasting typically a few weeks to a few months and must be repeated periodically if used for longer-term management.

Emerging Therapies

The myasthenia gravis treatment landscape is evolving rapidly:

• Efgartigimod (FcRn antagonist): This treatment reduces IgG autoantibody levels by blocking the recycling receptor, which normally prolongs antibody half-life. It represents a novel mechanism and has received approval in several countries.
• Rozanolixizumab and nipocalimab: Additional FcRn inhibitors in advanced development.
• CAR-T cell therapy: Under investigation for refractory autoimmune conditions.

---

Sources and Bibliography

• National Institute of Neurological Disorders and Stroke (NINDS) – Myasthenia Gravis
• Myasthenia Gravis Foundation of America (MGFA)
• Mayo Clinic – Myasthenia Gravis
• Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016